Welcome to Beacon Equity Research. Today is Sunday, 30 December 2007  
 Home     Covered Companies     News and Commentary     Our Team     Ratings     Contact Us     Charity     Affiliates    

Beacon Research Issues TraderNotes on LLSR, PMED, ANPI, PFE, SGP for December 27, 2007

Today’s TraderNotes include: Lantis Laser Inc. (Pink Sheets: LLSR), Paradigm Medical Industries, Inc. (OTCBB: PMED), Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI), Pfizer Inc. (NYSE: PFE), Schering-Plough Corporation (NYSE: SGP)


Lantis Laser Inc. (LLSR) TraderNote – LLSR Signed an “MOU” With LNGT


Lantis Laser Inc. (LLSR) closed yesterday at 0.30, no change from the previous close at the same price.  LLSR is finding momentum in trading as it recently signed a Memorandum of Understanding ("MOU") with Laser Energetics, Inc. (LNGT) to form a Joint Venture, based on equal participation, to market and distribute Laser Energetics BrightStar Alexandrite laser for dental applications.  Lantis Laser Inc. was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity, and large market potential. The Company plans to launch its OCT Dental Imaging System in the third quarter of 2008 as its first product.  Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license agreements with Lawrence Livermore National Laboratory and LightLab Imaging.  In yesterday’s trading, LLSR traded a volume of 76,791 shares within the range of 0.29 – 0.32.  Slow Stochastics indicator in yesterday’s daily chart reflects readings of 1.59 %K and 1.70 %D, to confirm oversold status upon crossing over the 20% level upwards. 


Paradigm Medical Industries, Inc. (PMED) TraderNote – PMED Boosted by Strong Demand for Its Dicon LD400 Product in the UK


Paradigm Medical Industries, Inc. (PMED) closed yesterday at 0.0023, a positive change of 0.0011 or an increase of 91.67% from the previous close of 0.0012.  Paradigm Medical Industries, Inc. (Salt Lake City, UT) currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed “The UBM Company” (Ultrasound BioMicroscope).  The company recently disclosed it has received an order for 30 Dicon LD400 Visual Fields Analyzers (Perimeters) from one of the largest optical chains in the United Kingdom.  The retail value of this order exceeds $250,000.  In yesterday’s trading, PMED heavily traded with a volume of 71.63M shares within the range of 0.0012 – 0.0024. 


Angiotech Pharmaceuticals, Inc. (ANPI) TraderNote – ANPI Received FDA Authorization to Begin Phase I Clinical Trial for Its MultiStem Product


Angiotech Pharmaceuticals, Inc. (ANPI) actively traded yesterday in 2,235 transactions with a volume of 1.12M shares valued at $3.76M.  Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.  Athersys, Inc. (ATHX) and Angiotech Pharmaceuticals, Inc. (ANPI) recently announced that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStem in the treatment of acute myocardial infarction (AMI).  Angiotech and Athersys entered into an agreement in May 2006 to co-develop and commercialize MultiStem, Athersys' non-embryonic stem cell platform technology, for use in the indications of AMI and peripheral vascular disease.  The companies believe that this represents the first clinical study of a scalable, allogeneic cell product injected directly into and around the zone of myocardial injury from an intra-coronary approach.  In yesterday’s trading, ANPI closed at 3.35, a positive change of 0.07 or an increase of 2.13% from the previous close of 3.28. 


Pfizer Inc. (PFE) TraderNote – PFE Actively Traded Yesterday with 21,442,051 Shares Valued at US $487.5M


Pfizer Inc. (PFE) heavily traded yesterday with 21,442,051 shares valued at $487.5M.  Pfizer, Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals in the United States, Europe, Canada, Asia, and Latin America. Its Pharmaceutical segment offers products for cardiovascular and metabolic diseases, such as Lipitor for elevated cholesterol levels in the blood; Norvasc for hypertension; Caduet for cardiovascular events; Chantix/Champix for smoking cessation; and Exubera, the inhaled human insulin therapy for glycemic control.  Pfizer Inc. recently announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer’s once-weekly two-dose antibiotic under FDA review for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).  In yesterday’s trading, PFE closed at 23.20, a slight negative change of 0.13 or a slight decrease of 0.56% from the previous close of 23.33. 


Schering-Plough Corporation (SGP) TraderNote – SGP Strengthened by Extension in Marketing Rights for REMICADE and Golimumab to 15 Years


Schering-Plough Corporation (SGP) closed yesterday at 27.16, a positive change of 0.03 or an increase of 0.11% from the previous close of 27.13. Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world.  Schering-Plough Corporation, together with Centocor, Inc., recently announced that they have revised their 1998 distribution agreement of both REMICADE (infliximab), an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy.  Effective upon regulatory approval of golimumab in the EU, the revised agreement will extend the duration of Schering-Plough's rights to exclusively market REMICADE outside the United States beyond 2014.  Schering-Plough's marketing rights to both products will now extend for 15 years after the first golimumab commercial sale.  In yesterday’s trading, SGP traded a volume of 6,972,814 shares within the range of 26.98 – 27.29. 


Beacon Equity Research Disclosure


The analysts contributing to this report do not hold any shares of Lantis Laser (LLSR).  Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report.  Beacon Equity Research and its affiliates have been directly compensated a total of nine thousand dollars directly from Lantis Laser for enrollment of LLSR in its research program.  This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
< Prev   Next >

Copyright 2007 Beacon Equity Research